Startup of the week: Vibrant Medical

Stroke is one of the most time-sensitive medical emergencies, yet in hospital settings, dangerous changes in a patient’s condition may occur between scheduled neurological checks. For high-risk patients, that gap can mean losing valuable time before a stroke is detected and treatment can begin.

Vibrant Medical is working to change that.

The company is developing a continuous wearable ultrasound monitoring system designed to track cerebral blood flow in hospitalized patients at high risk of stroke. Its approach combines a disposable neck patch with a bedside AI unit, creating a system that can continuously monitor changes rather than relying only on periodic assessments.

By providing ongoing insight into cerebral blood flow, Vibrant Medical aims to help clinical teams identify potentially dangerous changes earlier and support faster intervention when every minute matters.

The company is currently pre–first-in-human, with initial human testing planned for Q4 2026. As it moves toward clinical validation, Vibrant Medical is also navigating one of the most common challenges in MedTech: generating the clinical evidence investors want to see while simultaneously raising the capital required to produce that evidence.

Its development reflects a broader shift in medical technology toward continuous monitoring systems that can give healthcare professionals more timely information about patients whose conditions can change rapidly.

We spoke with the founder of Vibrant Medical about the motivation behind building the company, the challenge of balancing clinical development and fundraising, and what it takes to bring a new medical device from an idea toward real-world use.

Tell us about Vibrant Medical.

Vibrant Medical is a MedTech startup developing the world's first continuous wearable ultrasound monitor for in-hospital stroke detection. Our disposable neck patch and bedside AI unit continuously track cerebral blood flow in high-risk hospitalized patients, so care teams can catch a stroke in the critical window instead of during the next scheduled check. We're pre-FIH today, with first-in-human testing planned for Q4 2026.

What made you become an entrepreneur?

I've always loved building things and always dreamed of taking something from zero to everything, watching an idea become a real, working product from the ground up. Entrepreneurship was the natural outlet for that: it's the only path where you get to build the whole thing yourself, not just a piece of it.

What is the most challenging part of running your own startup?

Wearing every hat at once. In one week I might be refining the regulatory strategy, prepping an investor deck, and reviewing sensor prototypes with our technical team. The hardest part isn't any single skill, it's constantly context-switching while still moving the clinical and fundraising timelines forward in parallel.

What is the biggest challenge you have faced when looking for funding?

The classic medtech chicken-and-egg problem: investors want to see clinical data before committing, but you need capital to run the first-in-human study that generates that data. We've had to structure our raise in tranches and lean hard on our team's track record and clinical advisors to bridge that gap.

What is the most rewarding aspect of entrepreneurship?

Knowing that if we get this right, we could change the outcome for millions of people around the world. That, plus building something real from scratch with people I trust completely, makes the hard days worth it.

Towards Earlier Stroke Detection

Vibrant Medical’s work addresses a fundamental challenge in acute care: how to detect critical neurological changes earlier and more continuously.

For patients at high risk of stroke, monitoring is often a race against time. By combining wearable ultrasound technology with continuous cerebral blood flow monitoring, the company aims to give clinical teams an additional layer of information between scheduled checks.

The next major milestone will be first-in-human testing, an important step toward understanding how the technology performs in real clinical environments and building the evidence needed for future adoption.

For a startup working at the intersection of medical devices, AI, and acute patient care, the challenge is not only developing the technology, but also proving that it can fit into clinical workflows and ultimately help clinicians act sooner when patients need it most.

Learn more about Vibrant Medical on their website: https://vibrant-med.com/